Article

Seminar spotlights ophthalmic research

"A seminar designed to help investors identify opportunities and evaluate potential investment in ophthalmic research will take place in Fort Lauderdale, FL, April 29. The seminar, entitled ?Unmet Needs: Emerging Frontiers in Ophthalmic Science,? is being organized by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER). "

Rockville, MD -A seminar designed to help investors identify opportunities and evaluate potential investment in ophthalmic research will take place in Fort Lauderdale, FL, April 29.

The seminar, entitled “Unmet Needs: Emerging Frontiers in Ophthalmic Science,” is being organized by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER).

The seminar aims to help investors better understand the scientific and commercial environment of ophthalmic research. Sessions will describe unmet needs as well as promising treatments for retinal disease and ocular surface disorders.

“Modern science and industry have made tremendous progress in preventing and treating eye disease,” said lead organizer Nicolas Bazan, MD, PhD, “but there is still a great need to develop more effective treatments and devices to help alleviate these conditions. Many areas of ophthalmic science require additional research support-and they offer opportunities for commercial development.

“AFER’s Investors Seminar will provide a unique opportunity for private equity managers, venture capitalists, analysts, and others to assess the value of emerging early-  and late-stage treatments through an independent scientific and commercial lens,” Dr. Bazan continued. “They will also join in discussion with the scientists and commercial experts who are working at the cutting edge of these fields.”

The speakers will discuss the epidemiology of retinal diseases and ocular surface disorders, unmet needs, desired clinical outcomes, regulatory considerations, emergence of potential treatment algorithms, limitations of current therapies, and the drivers of market potential.

Complete program, venue and registration information is available at www.arvofoundation.org/investors.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.